Valeant Pharmaceuticals International provided earnings guidance for the year 2015 and 2016. The company still expects revenue of $10.4 billion to $10.5 billion for 2015 and adjusted EPS of $10.23 to $10.33 a share.

For 2016 the company is targeting full year revenue of $12.5 billion to $12.7 billion and adjusted EPS of $13.25 to $13.75 a share.